But the drugmaker’s adjusted earnings topped Wall Street’s view, and it narrowed its full-year adjusted earnings forecast on Monday. Merck also announced on Monday that the Food and Drug Administration gave breakthrough therapy designation to Keytruda for advanced non-small cell lung cancer that has progressed on or following platinum-based chemotherapy.

Click here to read original article